Publication | Open Access

Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer

Surgical OncologyGastrointestinal OncologyMedicinePathologyColorectal CancerMetastatic Colorectal CancerFurther LinesOncologyRadiation OncologyKras Wild-type Patients